IP Library Granted Patent US 11,026,407
Granted Patent B2
US 11,026,407 · App. 16/530,030 · Granted Jun 8, 2021

Mice expressing a limited immunoglobulin light chain repertoire

Inventors: John McWhirter (Hastings-on-Hudson, NY); Lynn Macdonald (Harrison, NY); Sean Stevens (Del Mar, CA); Andrew J. Murphy (Croton-on-Hudson, NY)
Assignee: Regeneran Pharmaceuticals, Inc.
A01K67/0278A01K67/0275C07K16/00C07K16/462C12N15/8509A01K2207/15A01K2217/072A01K2217/15A01K2227/105A01K2267/01C07K2317/21C07K2317/24C07K2317/515C07K2317/565C07K2317/567C07K2317/76C07K2317/92C07K2319/30C12N2800/204
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,026,407
App. No.
16/530,030
Granted
Jun 8, 2021
Kind
B2
Abstract

A genetically modified mouse is provided, wherein the mouse expresses an immunoglobulin light chain repertoire characterized by a limited number of light chain variable domains. Mice are provided that present a choice of two human light chain variable gene segments such that the immunoglobulin light chains expresses by the mouse comprise one of the two human light chain variable gene segments. Methods for making bispecific antibodies having universal light chains using mice as described herein, including human light chain variable regions, are provided. Methods for making human variable regions suitable for use in multispecific binding proteins, e.g., bispecific antibodies, and host cells are provided.

Claims (21)

1. A method for generating a human immunoglobulin heavy or light chain variable region sequence comprising the steps of:

(a) immunizing a genetically modified mouse with an antigen of interest, wherein the genetically modified mouse comprises in its germline genome:

(i) exactly two unrearranged human immunoglobulin Vκ gene segments and five unrearranged human immunoglobulin Jκ fix gene segments operably linked to a mouse immunoglobulin light chain constant region sequence at the endogenous kappa light chain loci of the mouse, wherein the two unrearranged human immunoglobulin Vκ gene segments are a human Vκ1-39 gene segment and a human Vκ3-20 gene segment; and

(ii) one or more unrearranged human immunoglobulin V H gene segments, one or more unrearranged human immunoglobulin D H gene segments, and one or more unrearranged human immunoglobulin J H gene segments operably linked to a mouse immunoglobulin heavy chain constant region sequence at the endogenous heavy chain loci of the mouse;

wherein the unrearranged human immunoglobulin heavy chain and kappa light chain gene segments of the genetically modified mouse are capable of rearranging and encoding human immunoglobulin variable domains of an antibody, wherein the genetically modified mouse does not comprise endogenous immunoglobulin Vκ or Jκ gene segments that are capable of rearranging to form an immunoglobulin light chain variable region sequence; and

(b) determining a human immunoglobulin heavy or light chain variable region sequence that encodes a human heavy or kappa light chain variable domain of an antibody, respectively, that specifically binds the antigen and that was generated by the genetically modified mouse.

2. The method of claim 1 , wherein the five unrearranged human immunoglobulin Jκ gene segments are a human Jκ1 gene segment, a human Jκ2 gene segment, a human Jκ3 gene segment, a human Jκ4 gene segment, and a human Jκ5 gene segment.

3. The method of claim 1 , wherein the mouse light chain constant region is a mouse Cκ constant region.

4. The method of claim 1 , wherein the human Vκ1-39 gene segment in the germline genome of the genetically modified mouse is a human germline Vκ1-39 gene segment and the human Vκ3-20 gene segment in the germline genome of the genetically modified mouse is a human germline Vκ3-20 gene segment.

5. The method of claim 1 , wherein the germline genome of the genetically modified mouse comprises in order: the human Vκ1-39 gene segment, the human Vκ3-20 gene segment, the human Jκ1 gene segment, the human Jκ2 gene segment, the human Jκ3 gene segment, the human Jκ4 gene segment, and the human Jκ5 gene segment.

6. The method of claim 5 , wherein the mouse light chain constant region is a mouse Cκ constant region.

7. The method of claim 1 , wherein the genetically modified mouse comprises a nonfunctional λ light chain locus.

8. The method of claim 1 , wherein the genetically modified mouse comprises a functional λ light chain locus.

9. A mouse embryonic stem (ES) cell comprising in its genome:

a) exactly two unrearranged human immunoglobulin Vκ gene segments and five unrearranged human immunoglobulin Jκ gene segments operably linked to a mouse immunoglobulin light chain constant region sequence at the endogenous kappa light chain loci of the mouse, wherein the two unrearranged human immunoglobulin Vκ gene segments are a human Vκ1-39 gene segment and a human Vκ3-20 gene segment; and

b) one or more unrearranged human immunoglobulin V H gene segments, one or more unrearranged human immunoglobulin D H gene segments, and one or more unrearranged human immunoglobulin J H gene segments operably linked to a mouse immunoglobulin heavy chain constant region sequence at the endogenous heavy chain loci of the mouse ES cell.

10. The ES cell of claim 9 , wherein the five unrearranged human immunoglobulin Jκ gene segments are a human Jκ1 gene segment, a human Jκ2 gene segment, a human Jκ3 gene segment, a human Jκ4 gene segment, and a human Jκ5 gene segment.

11. The ES cell of claim 9 , wherein the mouse light chain constant region is a mouse Cκ constant region.

12. The ES cell of claim 9 , wherein the human Vκ1-39 gene segment is a human germline Vκ1-39 gene segment and the human Vκ3-20 gene segment is a human germline Vκ3-20 gene segment.

13. The ES cell of claim 9 , wherein the genome of the ES comprises in order: the human Vκ1-39 gene segment, the human Vκ3-20 gene segment, the human Jκ1 gene segment, the human Jκ2 gene segment, the human Jκ3 gene segment, the human Jκ4 gene segment, and the human Jκ5 gene segment.

14. A mouse embryo derived from the ES cell of claim 9 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 13, 2019
From: MCWHIRTER, JOHN; MACDONALD, LYNN; STEVENS, SEAN; MURPHY, ANDREW J.
To: REGENERON PHARMACEUTICALS, INC.
Reel/Frame 050035/0632 →
Continuity (9)
Continuation 16128360 · Sep 11, 2018
Continuation 15700973 · Sep 11, 2017
Continuation 13798455 · Mar 13, 2013
Continuation In Part 13488628 · Jun 5, 2012
Continuation In Part 13412936 · Mar 6, 2012
Continuation In Part 13093156 · Apr 25, 2011
Continuation In Part 13022759 · Feb 8, 2011
Provisional Application 61302282 · Feb 8, 2010
Related Publication 20200024368A1 · Jan 23, 2020
Cited By (1)
US 12,389,888